What does a Model for End-Stage Liver Disease Sodium (MELD-Na) score of 30 indicate regarding prognosis and recommended management?

MELD-Na 30 Interpretation

A MELD-Na score of 30 indicates severe liver disease with high short-term mortality risk (approximately 35-50% at 3 months) and warrants urgent evaluation for liver transplantation and consideration for ICU-level monitoring. 1

Prognostic Significance

A MELD-Na of 30 places the patient in a critical risk category:

• 3-month mortality: Research demonstrates that patients with MELD-Na scores in the 30-35 range have approximately 35.4% mortality at 3 months, with risk escalating sharply above this threshold 2
• Severity threshold: MELD-Na ≥30 has been identified as an independent risk factor for mortality in fulminant hepatic failure (hazard ratio 4.5), suggesting these patients require emergent intervention 3
• ACLF context: In acute-on-chronic liver failure (ACLF), traditional MELD and MELD-Na scores may actually underestimate mortality because they don't fully capture extrahepatic organ failures 4

Immediate Management Priorities

Transplant Evaluation

Patients with MELD-Na ≥30 should be immediately referred for liver transplantation evaluation. This is particularly critical in specific contexts:

• HBV-related ACLF: Guidelines explicitly recommend transplant consideration for MELD >30 despite antiviral treatment, especially without early virologic response 1
• Fulminant hepatic failure: MELD ≥30 is the sole independent predictor requiring emergent transplantation for survival 3

ICU Assessment

Consider ICU admission based on 1:

• Need for organ support (vasopressors, mechanical ventilation, renal replacement therapy)
• Grade III-IV hepatic encephalopathy
• Septic shock or massive bleeding
• Timing: Within 6 hours of diagnosis when indicated

Monitoring Intensity

• Serial reassessment: Prognosis should be reassessed after 3-7 days of treatment, as scores are dynamic 1
• Delta MELD-Na: If the score increases (Delta MELD-Na >0) after 14 days of treatment, mortality risk jumps to 65.9% versus 15.8% for stable/improving scores 2

Important Caveats

Contraindications to aggressive intervention that should temper management despite high MELD-Na 1:

• Severe comorbidities: GOLD 3-4 pulmonary disease, NYHA class III-IV cardiac disease with ACLF-3
• Advanced malignancy (life expectancy <6 months)
• Severe frailty with sarcopenia or Karnofsky performance status ≤40

Context matters: The MELD-Na score performs best for predicting mortality in standard cirrhosis but has limitations:

• In ACLF with multiple organ failures, ACLF-specific scores (CLIF-C ACLF, NACSELD) may provide better prognostication 4
• For alcoholic hepatitis specifically, MELD-Na outperforms other scoring systems for 90-day mortality prediction 5

Clinical Decision Algorithm

1. MELD-Na 30 confirmed → Immediate transplant center contact
2. Assess for ACLF → If present, use ACLF-specific scores for refined prognosis
3. Evaluate contraindications → Screen for severe comorbidities that preclude transplant
4. Determine acuity → ICU admission if organ support needed or grade III-IV encephalopathy
5. Reassess at 3-7 days → Calculate Delta MELD-Na to guide ongoing management intensity

The key principle: MELD-Na 30 represents a critical threshold where mortality risk demands aggressive intervention unless specific contraindications exist.